QualityStocks News - International Stem Cell Expands Protection of Proprietary Technology with Key Patent for Liver Disease Program

Share Article

Patent covers method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells.

QualityStocks would like to highlight International Stem Cell Corporation (OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).

In the company’s news yesterday,

International Stem Cell Corporation announced that the United States Patent and Trademark Office (USPTO) awarded the company with a patent for a method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells. Allowing the production of necessary quantities of precursor cells in a more efficient and cost effective manner, this new patent is a key part of ISCO’s metabolic liver disease program.

The patent, 8,268,621, adds to the company’s growing intellectual property portfolio relating to the development of potential treatments for diseases without cure using human parthenogenetic Stem Cells (hpSC). These unique pluripotent stem cells offer the possibility of reducing the cost of health care while avoiding the ethical issues of using fertilized human embryos. In addition to supporting the company’s current liver disease program, this new patented method can be used as a way of creating pancreatic and endocrine cells for use in future studies of diabetes and other metabolic disorders.

According to the press release, ISCO has the largest collection of hpSC, including cell lines which immune-match millions of individuals and potentially reduce tissue rejection issues. The company is focusing its therapeutic development efforts on three clinical applications where cell and tissue therapy is already proven but where there currently is an insufficient supply of safe and efficacious cells: Parkinson’s disease, inherited/metabolic liver diseases, and corneal blindness.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read full disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website